» Articles » PMID: 31861681

Overexpression of Mitochondrial IF1 Prevents Metastatic Disease of Colorectal Cancer by Enhancing Anoikis and Tumor Infiltration of NK Cells

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2019 Dec 22
PMID 31861681
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Increasing evidences show that the ATPase Inhibitory Factor 1 (IF1), the physiological inhibitor of the ATP synthase, is overexpressed in a large number of carcinomas contributing to metabolic reprogramming and cancer progression. Herein, we show that in contrast to the findings in other carcinomas, the overexpression of IF1 in a cohort of colorectal carcinomas (CRC) predicts less chances of disease recurrence, IF1 being an independent predictor of survival. Bioinformatic and gene expression analyses of the transcriptome of colon cancer cells with differential expression of IF1 indicate that cells overexpressing IF1 display a less aggressive behavior than IF1 silenced (shIF1) cells. Proteomic and functional in vitro migration and invasion assays confirmed the higher tumorigenic potential of shIF1 cells. Moreover, shIF1 cells have increased in vivo metastatic potential. The higher metastatic potential of shIF1 cells relies on increased cFLIP-mediated resistance to undergo anoikis after cell detachment. Furthermore, tumor spheroids of shIF1 cells have an increased ability to escape from immune surveillance by NK cells. Altogether, the results reveal that the overexpression of IF1 acts as a tumor suppressor in CRC with an important anti-metastatic role, thus supporting IF1 as a potential therapeutic target in CRC.

Citing Articles

Ablation of impairs metabolic reprogramming and proliferation of T lymphocytes and compromises mouse survival.

Romero-Carraminana I, Dominguez-Zorita S, Esparza-Molto P, Cuezva J iScience. 2024; 27(6):109863.

PMID: 38799559 PMC: 11126974. DOI: 10.1016/j.isci.2024.109863.


The ATPase Inhibitory Factor 1 (IF1) Contributes to the Warburg Effect and Is Regulated by Its Phosphorylation in S39 by a Protein Kinase A-like Activity.

Cuezva J, Dominguez-Zorita S Cancers (Basel). 2024; 16(5).

PMID: 38473373 PMC: 10931224. DOI: 10.3390/cancers16051014.


Anoikis-related genes as potential prognostic biomarkers in gastric cancer: A multilevel integrative analysis and predictive therapeutic value.

Lin Y, Liu J IET Syst Biol. 2024; 18(2):41-54.

PMID: 38377622 PMC: 10996445. DOI: 10.1049/syb2.12088.


Anoikis related genes may be novel markers associated with prognosis for ovarian cancer.

Yang C, Zhu L, Lin Q Sci Rep. 2024; 14(1):1564.

PMID: 38238592 PMC: 10796408. DOI: 10.1038/s41598-024-52117-0.


Anoikis-related signature identifies tumor microenvironment landscape and predicts prognosis and drug sensitivity in colorectal cancer.

Pan Y, Xu W, Huang M, Lu Y, Zhou Y, Teng Y J Cancer. 2024; 15(3):841-857.

PMID: 38213716 PMC: 10777033. DOI: 10.7150/jca.91627.


References
1.
Cuezva J, Ortega A, Willers I, Sanchez-Cenizo L, Aldea M, Sanchez-Arago M . The tumor suppressor function of mitochondria: translation into the clinics. Biochim Biophys Acta. 2009; 1792(12):1145-58. DOI: 10.1016/j.bbadis.2009.01.006. View

2.
Garcia-Aguilar A, Martinez-Reyes I, Cuezva J . Changes in the Turnover of the Cellular Proteome during Metabolic Reprogramming: A Role for mtROS in Proteostasis. J Proteome Res. 2019; 18(8):3142-3155. DOI: 10.1021/acs.jproteome.9b00239. View

3.
Riihimaki M, Hemminki A, Sundquist J, Hemminki K . Patterns of metastasis in colon and rectal cancer. Sci Rep. 2016; 6:29765. PMC: 4945942. DOI: 10.1038/srep29765. View

4.
Casimiro M, Crosariol M, Loro E, Li Z, Pestell R . Cyclins and cell cycle control in cancer and disease. Genes Cancer. 2013; 3(11-12):649-57. PMC: 3636749. DOI: 10.1177/1947601913479022. View

5.
DAlterio C, Buoncervello M, Ierano C, Napolitano M, Portella L, Rea G . Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1. J Exp Clin Cancer Res. 2019; 38(1):432. PMC: 6819555. DOI: 10.1186/s13046-019-1420-8. View